Celcuity Inc. CELC

REVTORPYK (gedatolisib) REVTORPYK (gedatolisib) vial and box REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic settingREVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 to comprehensively blockade the PI3K/AKT/mTOR (“PAM”) pathwayIn the PIK3CA wild-type coho

While early-stage biopharmaceutical firms typically lack historic multi-year revenue growth (0% 3-year CAGR at $0.00 TTM revenue), positive operating cash flow generation (-$153.3M TTM), or positive free cash flow conversion (-$192.3M TTM), Celcuity Inc. (NASDAQ:CELC) enters its commercial rollout backed by a balance sheet holding $754 million in cash and equivalents. Although historic return on […]